Sentence examples for dosage form development from inspiring English sources

Polymeric excipients possessing an established profile for commercial dosage form development were selected.

The designed system offers a resource sparing primary screen for drug excipient chemical compatibility for solid dosage form development.

Dosage form development involves design and development of a product with a defined target product quality profile, and a defined manufacturing process.

One of the most critical elements of dosage form development is to apply a unified view of formulation and process development.

Dosage form development should focus on overcoming the limitations facing oral peptides delivery as degradation by proteolytic enzymes and poor absorption in the gastrointestinal tract (GIT).

The model is a potentially useful in silico analysis tool that can be used for capsule dosage form development in accordance to quality by design (QbD) principles.

These materials can potentially be used for design of novel mucoadhesive dosage forms, development of solid drug dispersions and solubilisation of poorly soluble drugs, encapsulation technologies, preparation of nanoparticles, hydrogels, in situ gelling systems and electrically erodible materials.

However, using the FDA document for solid oral dosage forms, IVIVC relationships can be extrapolated to include non-solid oral delivery systems (FDA guidance for industry: extended-release oral dosage forms: development, evaluation and application of in vitro/in vivo correlations 1997).

While three or more formulations with different release rates are recommended, an IVIVC may also be defined with a minimum of two or more formulations having different release rates (FDA guidance for industry: extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlations 1997).

As recommended by the FDA guidance (FDA guidance for industry: extended-release oral dosage forms: development, evaluation and application of in vitro/in vivo correlations 1997), Figs. 8 and 9 depict the pooled IVIVCs for the 50 50 (fast release) and 75:25 (slow release) risperidone PLGA formulations.

Use an appropriate deconvolution technique (e.g., Nelson Wagner) to calculate the in vivo absorption after which a correlation may be obtained by comparing in vivo behavior with in vitro release to establish an IVIVC FDAA guidance for industry: extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlations 1997).